Anticoagulation in the Early Phase of Non-Valvular Atrial Fibrillation-Related Acute Ischemic Stroke: Where Do We Stand?

Italian Journal of Medicine - Italy
doi 10.4081/itjm.2019.1111
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

PAGEPress Publications

Related search

Resolution of Left Atrial Thrombus by Dabigatran Etexilate Administered During Acute-Phase Cardioembolic Stroke in Five Patients With Non-Valvular Atrial Fibrillation

Nosotchu
2015English

Non-Cardioembolic Risk Factors in Atrial Fibrillation-Associated Ischemic Stroke

PLoS ONE
Multidisciplinary
2018English

Risk of Ischemic Stroke in Thyrotoxic Atrial Fibrillation

Clinical Endocrinology
EndocrinologyMetabolismDiabetes
2019English

Patients’ Priorities for Oral Anticoagulation Therapy in Non-Valvular Atrial Fibrillation: A Multi-Criteria Decision Analysis

American Journal of Cardiovascular Drugs
MedicineCardiovascular MedicinePharmacologyCardiology
2018English

Blockchain in Academia: Where Do We Stand and Where Do We Go?

2020English

Cost-Effectiveness of Apixaban for Stroke Prevention in Non-Valvular Atrial Fibrillation in Saudi Arabia

Annals of Saudi Medicine
Medicine
2019English

Where Do We Come From? Where Are We Going? Adverse Outcomes in Catheter Ablation for Atrial Fibrillation

Circulation: Arrhythmia and Electrophysiology
MedicineCardiovascular MedicinePhysiologyCardiology
2014English

High Energy Neutrino Astronomy: Where Do We Stand, Where Do We Go?

Physics of Particles and Nuclei
High Energy PhysicsNuclear
2018English

Schistosomiasis Vaccines: Where Do We Stand?

Parasites and Vectors
ParasitologyInfectious Diseases
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy